Clinical trials: NSCLC Adenocarcinoma
Pancreatic Cancer, Breast Cancer
Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors
Study of NGM831 as Monotherapy and in Combination with Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors
- Conditions
- Pancreatic Cancer, Breast Cancer, Gastric Cancer, Non-small Cell Lung Cancer
- Trial name
- NCT05215574
- Testing
- NGM831, NGM831 plus pembrolizumab (KEYTRUDA®), NGM831 and NGM438 plus pembrolizumab (KEYTRUDA®)
- Where
- 9 sites in United States
- Volunteers
- 130 people
- Sponsor
- NGM Biopharmaceuticals, Inc
Melanoma (Excluding Uveal Melanoma), Cervical Carcinoma
A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)
This is a Phase 1, multiple dose, ascending dose escalation study to define a MTD/RD and regimen of XmAb23104, to describe safety and tolerability, to assess PK and immunogenicity, and to preliminarily assess anti-tumor activity…
- Conditions
- Melanoma (Excluding Uveal Melanoma), Cervical Carcinoma, Pancreatic Carcinoma, Breast Carcinoma That is Estrogen Receptor, Progesterone Receptor, and Her2 Negative
- Trial name
- DUET-3 (NCT03752398)
- Testing
- XmAb®23104, Yervoy® (ipilimumab)
- Where
- 18 sites in United States
- Volunteers
- 198 people
- Sponsor
- Xencor, Inc.
Non-Small Cell Lung Cancer, Medullary Thyroid Cancer
A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)
This is an open-label, first-in-human study designed to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity of selpercatinib (also known as LOXO-292) administered orally to participants…
- Conditions
- Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, Colon Cancer, Any Solid Tumor
- Trial name
- LIBRETTO-001 (NCT03157128)
- Testing
- LOXO-292
- Where
- 85 sites in United States, Australia and 14 more
- Volunteers
- 857 people
- Sponsor
- Eli Lilly and Company
Adenocarcinoma of Lung
To Compare Efficacy and Safety of CT-P16 and European Union-Approved Avastin as First-Line Treatment for Metastatic or Recurrent Non-Squamous Non-Small Cell Lung Cancer
To demonstrate that CT-P16 is similar to EU-Approved Avastin in terms of efficacy as determined by objective response rate (ORR) during the Induction Study Period
- Trial name
- NCT03676192
- Testing
- CT-P16, Avastin
- Where
- South Korea
- Volunteers
- 689 people
- Sponsor
- Celltrion
Non-small Cell Lung Cancer
Icotinib as an Adjuvant Therapy for Patients With Stage IIA-IIIA Adenocarcinoma With EGFR Mutation
Adjuvant therapy has been proved effective in treating earlier stage or less advanced non-small-cell lung cancer. This study is designed to evaluate the efficacy of icotinib as adjuvant therapy in treating stage IIA-IIIA…
- Trial name
- ICAPE (NCT02044328)
- Testing
- Icotinib
- Where
- China
- Volunteers
- 79 people
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
Solid Tumor, Pancreatic Ductal Adenocarcinoma (PDAC)
Study of JYP0015 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Evaluate the safety and antitumor activity of JYP0015 in adults with specific RAS mutant advanced solid tumors.
- Conditions
- Solid Tumor, Pancreatic Ductal Adenocarcinoma (PDAC), Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC)
- Trial name
- STAR (NCT06895031)
- Testing
- JYP0015
- Where
- China
- Volunteers
- 210 people
- Sponsor
- Guangzhou JOYO Pharma Co., Ltd
Lung Cancer
Combination Chemotherapy in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy such as gemcitabine, carboplatin, and paclitaxel use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00054392
- Testing
- carboplatin, gemcitabine hydrochloride, paclitaxel
- Where
- 57 sites in United States
- Sponsor
- Fox Chase Cancer Center
Metastatic Solid Tumor, Advanced Solid Tumor
Dose Escalation and Expansion Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid Tumors
A first-in-human, Phase I, open-label, multicenter study of WTX-124 administered as monotherapy and in combination with pembrolizumab to patients with advanced or metastatic solid tumors.
- Trial name
- NCT05479812
- Testing
- WTX-124, pembrolizumab
- Where
- 14 sites in United States
- Volunteers
- 156 people
- Sponsor
- Werewolf Therapeutics, Inc.
Advanced Malignant Tumors
A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors
This purpose of this study is to determine if experimental treatment with BMS-986488, alone, or in combinations is safe, tolerable, and has anti-cancer activity in patients with advanced malignant tumors.
- Trial name
- NCT06764771
- Testing
- BMS-986488, Adagrasib, Cetuximab
- Where
- 8 sites in United States, Australia and 1 more
- Volunteers
- 437 people
- Sponsor
- Bristol-Myers Squibb
EGFR Mutation Status in aNSCLC Patients (Locally Advanced and/or Metastatic Disease) With Adenocarcinoma and Non-adenocarcinoma Histologies.
Europe-Japan Diagnostic Study for EGFR Testing
This is a non-interventional diagnostic, international, multicenter and non-comparative study of EGFR mutation status in aNSCLC patients (locally advanced and/or metastatic disease) with adenocarcinoma and non-adenocarcinoma…
- Trial name
- ASSESS (NCT01785888)
- Where
- 57 sites in France, Germany and 6 more
- Volunteers
- 1,311 people
- Sponsor
- AstraZeneca
Metastatic Solid Tumors, Advanced Non-squamous Non-small-cell Lung Cancer
A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification
This is a first-in-human (FIH), open-label, multicenter, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BGB-53038 as…
- Conditions
- Metastatic Solid Tumors, Advanced Non-squamous Non-small-cell Lung Cancer, Advanced Colorectal Cancer, Advanced Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT06585488
- Testing
- BGB-53038, Tislelizumab, Cetuximab
- Where
- 17 sites in United States, Australia and 3 more
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- BeOne Medicines
Non-small-cell Lung Cancer, Squamous Cell Carcinoma
Study of AXL1717 Compared to Docetaxel to Treat Squamous Cell Carcinoma or Adenocarcinoma of the Lung
The purpose of this study is to compare effectiveness and safety of experimental anticancer medicine, AXL1717, and docetaxel in patients with squamous cell carcinoma or adenocarcinoma of the lung.
- Conditions
- Non-small-cell Lung Cancer, Squamous Cell Carcinoma, Adenocarcinoma of the Lung
- Trial name
- NCT01561456
- Testing
- AXL1717, Docetaxel
- Where
- 24 sites in Belarus, Hungary and 3 more
- Volunteers
- 100 people
- Sponsor
- Axelar AB
Solid Tumors, Urothelial Carcinoma
A Study Evaluating MM-310 in Patients With Solid Tumors
MM-310 is a liposomal formulation of a docetaxel prodrug that targets the EphA2 receptor on cancer cells. Docetaxel is an approved chemotherapeutic drug.This study is a Phase 1 open-label study of MM-310 in patients with solid…
- Conditions
- Solid Tumors, Urothelial Carcinoma, Gastric Carcinoma, Squamous Cell Carcinoma of the Head and Neck
- Trial name
- NCT03076372
- Testing
- MM-310
- Where
- 5 sites in United States
- Volunteers
- 34 people
- Sponsor
- Merrimack Pharmaceuticals
Cancer
RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma
RATIONALE: Monoclonal antibodies, such as RAV12, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00101972
- Testing
- monoclonal antibody RAV12
- Where
- 5 sites in United States
- Volunteers
- 53 people
- Sponsor
- MacroGenics
Bladder Cancer, Cervical Cancer
Varenicline or Nicotine Patch and Nicotine Gum in Helping Smokers in a Methadone Treatment Program Stop Smoking
RATIONALE: Varenicline, the nicotine patch, and nicotine gum help people stop smoking. It is not yet known whether varenicline is more effective than the nicotine patch given together with nicotine gum in helping smokers quit…
- Conditions
- Bladder Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer
- Trial name
- NCT00790569
- Testing
- nicotine, varenicline
- Where
- United States
- Volunteers
- 315 people
- Sponsor
- Butler Hospital
Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer
A Multi-Cancer, Multi-State, Platform Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Pancreatic Adenocarcinoma, Non-Small Cell Lung Cancer and Squamous Cell Carcinoma of the Head and Neck to Correlate Clinical, Molecular and Immunologic Parameters With DNA Methylation
This is a phase II, single center, open label, multi-cohort platform study to identify a signature in tumor tissues, blood or stool that might help identify participants who are more likely to experience tumor shrinkage or side…
- Conditions
- Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck
- Trial name
- DOME (NCT04262388)
- Testing
- Durvalumab, Oleclumab
- Where
- Canada
- Sponsor
- University Health Network, Toronto
Advanced Cancer, Pancreatic Cancer
Study of Nivolumab Plus Chemotherapy in Patients With Advanced Cancer (NivoPlus)
Determine Phase 2 dose of study drug
- Conditions
- Advanced Cancer, Pancreatic Cancer, Renal Cell Cancer, Non Small Cell Lung Cancer
- Trial name
- NivoPlus (NCT02423954)
- Testing
- Temsirolimus, Irinotecan, Irinotecan + capecitabine
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Western Regional Medical Center
Non-Small Cell Lung Cancer
Erlotinib Is Being Studied With Or Without An Investigational Drug, PF-02341066, In Patients With Lung Cancer
This is a Phase 1/2 study comparing the safety and anti-tumor activity of erlotinib alone versus erlotinib in combination with PF-02341066 in patients with advanced non-small cell lung cancer.
- Trial name
- NCT00965731
- Testing
- Erlotinib, PF-02341066
- Where
- 16 sites in United States
- Volunteers
- 27 people
- Sponsor
- Pfizer
Stage IV Melanoma, Advanced Lung Cancer
Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Advanced Cancer
The purpose of this study is to refine and pilot test educational material developed to educate and support patients receiving immunotherapy for advanced cancer.
- Conditions
- Stage IV Melanoma, Advanced Lung Cancer, Stage IV Non-Small Cell Lung Cancer, Unresectable Non-Small Cell Lung Carcinoma
- Trial name
- UPLIFT (NCT04670445)
- Testing
- Educational Video and QPL List, Usual Care
- Where
- United States
- Volunteers
- 199 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Lung Cancer
Carboplatin, Gemcitabine, and Thalidomide in Patients Undergoing Surgery for Stage II or III Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as carboplatin and gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00281827
- Testing
- carboplatin, gemcitabine hydrochloride, thalidomide
- Where
- 3 sites in United States
- Volunteers
- 22 people
- Sponsor
- Masonic Cancer Center, University of Minnesota